Omega‐6 Polyunsaturated Fatty Acids and Peripheral Artery Disease: An Individual Participant‐Level Analysis of 9 International Prospective Studies
Authors:
- Natalie L. WeirNWNatalie L. Weir
- Weihua GuanWGWeihua Guan
- Amy B. KargerAKAmy B. Karger
- Parveen K. GargPGParveen K. Garg
- Lina ThielLTLina Thiel
- Nathan TintleNTNathan Tintle
- Jyrki K. VirtanenJVJyrki K. Virtanen
- Rozenn N. LemaitreRLRozenn N. Lemaitre
- Brenton SwensonBSBrenton Swenson
- Bruce M. PsatyBPBruce M. Psaty
- Dariush MozaffarianDMDariush Mozaffarian
- 20 October 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Abstract
Background: Omega‐6 polyunsaturated fatty acids (PUFAs) have previously been associated with several peripheral artery disease (PAD) risk factors. We studied the association between individual omega‐6 PUFAs and incident PAD in a multicohort analysis. Methods: This study was conducted among participants from 9 cohorts (N=137 704; PAD cases=2014) in the FORCE (Fatty Acids and Outcomes Research Consortium) who were free of clinical PAD at baseline. Omega‐6 PUFAs were measured at baseline and with a median follow‐up of 14 years. Cox proportional hazards regression analyses were conducted in individual cohorts to evaluate associations of omega‐6 PUFAs (continuous cohort‐standardized interquintile ranges [difference between the medians of the 10th and 90th omega‐6 PUFAs percentiles] and cohort‐specific quintiles) with incident clinical PAD adjusting for prespecified covariates. Inverse‐variance weighted meta‐analysis was used to calculate the combined hazard ratios (HRs) and 95% CIs. Results: Linoleic acid (LA) was measured in all 9 cohorts, arachidonic acid in 8 (N=33 541; PAD cases=1766), dihomo‐γ‐LA and γ‐LA in 7 (N=29 861; PAD cases=1686), and eicosadienoic acid in 6 (N=27 538; PAD cases=1435). Only LA was associated with a lower risk of incident PAD (quintile 5 versus quintile 1: HR, 0.75 [95% CI, 0.64–0.89]; P =0.0009). Results did not differ in a statistically significant manner by age, sex, diabetes status, or smoking status. Conclusions: Results suggest that the omega‐6 PUFA LA may be protective against PAD, and other omega‐6 PUFAs are not associated with PAD incidence. This is further evidence that omega‐6 PUFA—disease relationships should be evaluated by individual fatty acids rather than grouped as total omega‐6 PUFAs.Keywords
This publication has 64 references indexed in Scilit:
- n–6 fatty acid biomarkers and incident atrial fibrillation: an individual participant-level pooled analysis of 11 international prospective studiesThe American Journal of Clinical Nutrition, 2023
- Linoleic Acid‐Rich Oil Alters Circulating Cardiolipin Species and Fatty Acid Composition in Adults: A Randomized Controlled TrialMolecular Nutrition & Food Research, 2022
- Omega-6 fats for the primary and secondary prevention of cardiovascular diseaseCochrane Database of Systematic Reviews, 2018
- Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention StudyEuropean Journal of Nutrition, 2015
- Gamma-Linolenic Acid Levels Correlate with Clinical Efficacy of Evening Primrose Oil in Patients with Atopic DermatitisAdvances in Therapy, 2014
- Repeated versus single measurement of plasma omega-3 fatty acids and risk of heart failureEuropean Journal of Nutrition, 2014
- Conjugated Equine Estrogens and Global Cognitive Function in Postmenopausal WomenWomen's Health Initiative Memory StudyJAMA, 2004
- Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery DiseaseJournal of General Internal Medicine, 1997
- Gamma‐linolenic acid treatment of rheumatoid arthritis. A randomized, placebo‐controlled trialArthritis & Rheumatism, 1996
- The cardiovascular health study: Design and rationaleAnnals of Epidemiology, 1991